Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Wipro Limited — how do they compare? Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B), while Wipro Limited trades at $1.83 (market cap $18.49B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 6.6× Wipro Limited's market cap, and Wipro Limited pays a 4.68% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | WIT | |
|---|---|---|
Market Cap | $121.95B | $18.49B |
Sector | Health | Technology |
52-Week High | $529.59 | $3.06 |
52-Week Low | $366.54 | $1.82 |
Enterprise Value | $116.69B | $16.42B |
Dividend Yield | — | 4.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
WIT trades at $1.82, down 2.15% with bearish technical signals. The company reported mixed Q1 2027 results with revenue below expectations but maintains solid profitability with 13.92% net margin. Recent partnerships with ServiceNow and AI initiatives show strategic positioning, though earnings misses in three consecutive quarters raise execution concerns.
The stock faces headwinds from recent earnings disappointments and bearish analyst sentiment (19% buy rating), but attractive valuation (P/E 13.86) and strong cash flow generation ($169.4B operating cash flow in 2025) provide fundamental support. Key risks include client spending uncertainty and competitive pressures in IT services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
